scispace - formally typeset
I

Ian D. Pavord

Researcher at University of Oxford

Publications -  654
Citations -  55329

Ian D. Pavord is an academic researcher from University of Oxford. The author has contributed to research in topics: Asthma & Sputum. The author has an hindex of 108, co-authored 575 publications receiving 47691 citations. Previous affiliations of Ian D. Pavord include John Radcliffe Hospital & University of Warwick.

Papers
More filters
Journal ArticleDOI

Chronic Airways Assessment Test: psychometric properties in patients with asthma and/or COPD

Mark D. Atkinson, +319 more
- 08 Apr 2023 - 
TL;DR: In this paper , the authors proposed a short patient-reported outcome (PRO) instrument called the chronic Airways Assessment Test (CAAT) to assess overall health status across different obstructive lung diseases.
Book ChapterDOI

Biologicals to Treat Allergy and Asthma

TL;DR: Anti-IgE and anti-IL-5 treatment fulfills an unmet need of specific subgroups of patients that do not respond to the classical inhaled steroid-based treatment many of whom need on systemic glucocorticoid treatment.
Journal ArticleDOI

Asthma control with ICS-formoterol reliever versus maintenance ICS and SABA reliever therapy: a post hoc analysis of two randomised controlled trials

TL;DR: There were no clinically important differences in the proportions of patients with ‘well-controlled’ or ‘partly controlled’ asthma symptoms, or proportions who improved or maintained their level of control, with as-needed budesonide–formoterol versus maintenance budesonides plus SABA.
Journal ArticleDOI

The relationship between Aspergillus Fumigatus sensitisation and sputum culture

TL;DR: This paper was published as Clinical and Experimental Allergy, 2009, 39 (12), p. 1937: British Society for Allergy and Clinical Immunology Annual Conference 2009 Abstracts, S2.
Proceedings ArticleDOI

S83 Clinical outcomes with mepolizumab therapy in routine practice in the oxford cohort

TL;DR: In routine clinical practice mepolizumab therapy is associated with rapid and significant reduction in oral steroid use and improvements in symptoms, and trends in improved quality of life including reduced anxiety and depression, which confirms the positive impact that MepolIZumab can have on the lives of patients.